APEC1621C: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Tazemetostat in Patients with Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex

Brief description of study

If you or your child has been diagnosed with recurrent or refractory solid tumors, you or your child may qualify to participate in a phase 2 study of a drug called tazemetostat in children with recurrent or refractory solid tumors (including non-Hodgkin lymphomas, histiocytoses and CNS tumors). The goal of this study is to find out what effects, good and or bad, the drug tazemetostat has on your tumor or type of cancer.

Clinical Study Identifier: s17-01131
ClinicalTrials.gov Identifier: NCT03213665
Principal Investigator: Sharon L Gardner
Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.